Join us for the next webinar in the
Industrializing Gene Therapy
Webinar On Demand! Register Today!
- 60 Minutes
As gene therapies move toward commercialization, the journey to manufacture a high-quality product while achieving economies of scale and reducing facility footprint can be challenging. Developing and optimizing your process development early on is critical for your company’s long-term success.
Attendees will learn how to:
- Achieve versatility with an automated, single-use end-to-end platform
- Optimize small-scale expression systems into a scalable process
- Achieve goals faster and better through collaboration
Mark S. Szczypka, PhD
Senior Director, Viral Vectors and Gene Therapy Technology
Ann Arbor, MI, USA
Mark Szczypka is Senior Director for Viral Vectors and Gene Therapy at Pall Biotech. Highly skilled in the field of cell culture applications, Mark previously held positions as President of SoloHill Engineering Inc., Director of Nephrology and Oncology at OncoImmune, and Senior Director Research and Development at RenaMed Biologics. In addition to his 20+ years of experience in cell culture, Mark has been published in numerous scientific journals. He received his Ph.D. in Biological Chemistry from the University of Michigan and completed his postdoctoral research at the University of Washington. Mark was awarded a Howard Hughes Research Scientist fellowship during his tenure at the University of Washington, and his work in gene therapy was published in the Journal Neuron and was highlighted on World News tonight.
Sr. Scientist, Scientific& Laboratory Services
Westborough, MA, USA
Heather Mallory is a senior scientist in the process development group at Pall Biotech. Prior to working at Pall, she worked with monoclonal antibodies and recombinant proteins at various companies including Xcellerex. She has years of purification experience working with viral vectors for gene therapy including AAV, Adenovirus, Syndbis virus and Lentivirus. She studied Biochemistry at SUNY Albany and Boston College. When not at work, Heather spends a lot of time hiking mountains with her two children, running, and listening to NPR.
Rachel Legmann, PhD
Senior Manager, Process Development Services
Westborough, MA, USA
Rachel Legmann joined Pall in 2014 and works in the process development services team where she leads upstream and downstream process development, scale-up, continuous bioprocessing and manufacturing support activities for the gene therapy and biologic market. Rachel is focused on combining biological and engineering aspects for maximizing process efficiencies and product quality. Prior to Pall, Rachel worked as a scientist and manager at a variety of biotechnology companies and academic institutions including Goodwin Biotechnology, Seahorse Biosciences, SBH Sciences and Harvard Medical School. She completed her PhD in Food Engineering and Biotechnology at the Technion-Israel Institute of Technology, Israel.
All fields required